Weekly intravesical bacillus Calmette-Guerin (BCG) alternating with epirubicin in Ta and T1 urothelial bladder cancer: An approach to decrease BCG toxicity

CONTEXT: Bacillus Calmette-Guerin (BCG) therapy is the standard treatment for nonmuscle-invasive bladder cancer (NMIBC). However, its toxicity is a major concern. AIM: If we reduce the number of BCG doses by half and replace the second half with epirubicin, we may have a lower toxicity while maintai...

Descripción completa

Detalles Bibliográficos
Autores principales: Ali-El-Dein, Bedeir, Barakat, Tamer S., Nabeeh, Adel, Ibrahiem, El-Housseiny I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3685738/
https://www.ncbi.nlm.nih.gov/pubmed/23798868
http://dx.doi.org/10.4103/0974-7796.110008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3685738/
https://www.ncbi.nlm.nih.gov/pubmed/23798868
http://dx.doi.org/10.4103/0974-7796.110008

Ejemplares similares